Literature DB >> 27756980

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.

.   

Abstract

Entities:  

Keywords:  Viekira Pak; chronic hepatitis C; dasabuvir; ombitasvir; paritaprevir; ribavirin; ritonavir

Year:  2016        PMID： 27756980      PMCID： PMC4993703          DOI： 10.18773/austprescr.2016.045

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  9 in total

Review 1.  Ledipasvir with sofosbuvir.

Authors: 
Journal:  Aust Prescr       Date:  2015-10-14

Review 2.  Treating hepatitis C - what's new?

Authors:  Alex J Thompson; Jacinta A Holmes
Journal:  Aust Prescr       Date:  2015-09-18

3.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

4.  An interferon-free antiviral regimen for HCV after liver transplantation.

Authors:  Paul Y Kwo; Parvez S Mantry; Eoin Coakley; Helen S Te; Hugo E Vargas; Robert Brown; Fredric Gordon; Josh Levitsky; Norah A Terrault; James R Burton; Wangang Xie; Carolyn Setze; Prajakta Badri; Tami Pilot-Matias; Regis A Vilchez; Xavier Forns
Journal:  N Engl J Med       Date:  2014-11-11       Impact factor: 91.245

5.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Authors:  Mark S Sulkowski; Joseph J Eron; David Wyles; Roger Trinh; Jay Lalezari; Chia Wang; Jihad Slim; Laveeza Bhatti; Joseph Gathe; Peter J Ruane; Richard Elion; Fritz Bredeek; Robert Brennan; Gary Blick; Amit Khatri; Krystal Gibbons; Yiran B Hu; Linda Fredrick; Gretja Schnell; Tami Pilot-Matias; Rakesh Tripathi; Barbara Da Silva-Tillmann; Barbara McGovern; Andrew L Campbell; Thomas Podsadecki
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

6.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Authors:  Pietro Andreone; Massimo G Colombo; Jeffrey V Enejosa; Iftihar Koksal; Peter Ferenci; Andreas Maieron; Beat Müllhaupt; Yves Horsmans; Ola Weiland; Henk W Reesink; Lino Rodrigues; Yiran B Hu; Thomas Podsadecki; Barry Bernstein
Journal:  Gastroenterology       Date:  2014-05-09       Impact factor: 22.682

7.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

9.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Authors:  Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
  9 in total
  3 in total

Review 1.  Sofosbuvir with velpatasvir.

Authors: 
Journal:  Aust Prescr       Date:  2017-08-09

Review 2.  Elbasvir/grazoprevir.

Authors: 
Journal:  Aust Prescr       Date:  2017-02-01

Review 3.  Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.

Authors:  Rohan Janardhan Meshram; Gunderao Hanumantrao Kathwate; Rajesh Nivarti Gacche
Journal:  Arch Virol       Date:  2022-01-28       Impact factor: 2.685
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.